Edition:
India

People: ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

56.66USD
30 Nov 2020
Change (% chg)

-- (--)
Prev Close
$56.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
419,281
52-wk High
$58.67
52-wk Low
$30.02

Davar, Gudarz 

Dr. Gudarz Davar serves as Executive Vice President - Head of Research and Development of the Company. Dr. Davar will be responsible for leading research and development activities at ACADIA and will serve as a member of the company's Executive Management Committee Dr. Davar joins ACADIA from Eli Lilly where he was Vice President, Head of Global Neurology Clinical Development, the senior leadership role responsible for the global development of all neuroscience and core Lilly biomedicines assets through clinical testing and life of the product. Under his leadership were the recent global approvals of Emgality ® for migraine prevention and U.S. approval for the treatment of cluster headache, as well as the U.S. approval of REYVOW ® as a first-in-class, novel, acute treatment for migraine. Prior to Eli Lilly, he served in senior leadership roles in neurology and clinical development at Allergan, Biogen Idec and Amgen. At Allergan, he led a global research and development and commercialization partnership focused on cognitive impairment and neurobehavioral symptoms in Alzheimer's disease. Dr. Davar received his medical degree from Dalhousie University in Halifax, Nova Scotia. He completed residency at University of Michigan Hospitals, Ann Arbor, Michigan and is board certified in Neurology.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stephen Biggar

319,959

Srdjan Stankovic

5,088,270

Stephen Davis

7,631,250

Elena Ridloff

1,990,870

Austin Kim

1,906,130

Gudarz Davar

--
As Of  31 Dec 2019